Proven Effective for Treatment-Resistant Depression
SPRAVATO® (intranasal esketamine) is an FDA-approved treatment introduced in 2019 for adults with treatment-resistant depression (TRD) and for major depressive disorder with suicidal thoughts or actions. Kansas Mental Health Medicine is a certified treatment center for the administration and monitoring of SPRAVATO® in a safe, supportive clinical setting.
Proven effective for treatment-resistant depression, SPRAVATO® may benefit adults with clinical depression who have had an inadequate response to two or more antidepressants. SPRAVATO® can now be prescribed with or without an oral antidepressant, depending on each patient’s individualized treatment plan.
To learn more about how SPRAVATO® works and whether it may be right for you, visit the official SPRAVATO® website: SPRAVATO® Treatment Information

Finding Relief For
The SPRAVATO® short-term studies evaluated efficacy results at 4 weeks
SPRAVATO® was also studied in a long-term, maintenance-of-effect trial
SPRAVATO® in combination with an oral antidepressant
SPRAVATO® was studied to see if the effect of treatment was maintained over time. The study showed:
- Patients who stayed on SPRAVATO® were less likely to experience a return of depressive symptoms (known as relapse) compared to patients who stopped therapy
- The trial compared patients who stayed on SPRAVATO® with an oral antidepressant to patients on a placebo nasal spray and oral antidepressant, long-term
Expert Monitoring & Compassionate Care
Administering SPRAVATO® requires specialized certification and a high level of clinical expertise. Meet the dedicated medical professionals who will guide you through your treatment protocol, ensuring your utmost comfort, safety, and progress during every in-office session.






































